Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New drug combo targets tough bladder cancers

NCT ID NCT04963153

First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 28 times

Summary

This early-stage trial tests a combination of two drugs—erdafitinib and enfortumab vedotin—for people with advanced bladder cancer that has spread and has specific FGFR2/3 gene changes. The goal is to find the safest and most effective dose and see if the combo can shrink or stabilize tumors. About 24 adults who have already tried chemotherapy are taking part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC UROTHELIAL CARCINOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Los Angeles General Medical Center

    Los Angeles, California, 90033, United States

  • Moffitt Cancer Center

    Tampa, Florida, 33612, United States

  • NYP/Weill Cornell Medical Center

    New York, New York, 10065, United States

  • Ohio State University Comprehensive Cancer Center

    Columbus, Ohio, 43210, United States

  • UCHealth University of Colorado Hospital

    Aurora, Colorado, 80045, United States

  • USC / Norris Comprehensive Cancer Center

    Los Angeles, California, 90033, United States

  • UT Southwestern/Simmons Cancer Center-Dallas

    Dallas, Texas, 75390, United States

  • University Health Network-Princess Margaret Hospital

    Toronto, Ontario, M5G 2M9, Canada

  • University of Pittsburgh Cancer Institute (UPCI)

    Pittsburgh, Pennsylvania, 15232, United States

Conditions

Explore the condition pages connected to this study.